Sangamo BioSciences


Cowen Optimistic on Sangamo Biosciences, Inc. (SGMO) Following 2Q:16 Results, Despite Recent Clinical Delays

Cowen analyst Ritu Baral was out with a favorable note on shares of Sangamo Biosciences, Inc. (NASDAQ:SGMO), after the biotech company released second-quarter results and provided …

Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

Sangamo BioSciences (NASDAQ:SGMO) was founded in 1995 ostensibly to commercialize zinc finger nuclease technology. Twenty years have passed since its founding and there …

Wedbush Reiterates Outperform On Sangamo, Raises PT To $28

In a research note published yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Sangamo BioSciences (NASDAQ:SGMO) and raised her price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts